PDS Biotechnology (NASDAQ: PDSB) — Perfil da empresa, notícias e dados financeiros
PDS Biotechnology develops immunotherapies for cancer and infectious diseases, utilizing its proprietary Versamune® platform.
PDS Biotechnology
PDS Biotechnology (NASDAQ:PDSB) specializes in the development of immunotherapies to fight various types of cancer and infectious diseases. Central to its operations is the Versamune® platform, a proprietary technology designed to activate the body's immune response towards specific diseases. PDS Biotechnology is currently focused on advancing its pipeline, including lead candidates for treating HPV-associated cancers and a collaboration for a COVID-19 vaccine. The company's objective is to deliver innovative treatments that improve patient outcomes and address unmet medical needs by harnessing the power of the immune system.
Resumo
Operações
Produtos e/ou serviços de PDS Biotechnology
- Versamune® technology, a platform aimed at advancing immune-activating therapies for cancer.
- PDS0101, a therapeutic vaccine targeting HPV-related cancers.
- Combination therapies leveraging PDS0101 for more effective cancer treatment options.
- Development of vaccines for infectious diseases utilizing Versamune® and other proprietary technologies.
- Research into novel immunotherapies aiming to treat a broader range of cancers.
- Collaboration with pharmaceutical companies to enhance and co-develop the existing pipeline of cancer immunotherapies.
equipe executiva do PDS Biotechnology
- Frank K. Bedu-AddoFounder, President, CEO, Interim CFO & Director
- Kirk V. ShepardChief Medical Officer
- Janetta TrochimiukController & Interim Principal Accounting Officer
- Gregory L. ConnChief Scientific Officer
- Spencer BrownSenior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Últimas notícias sobre a PDS Biotechnology
Principais indicadores financeiros
Resultados divulgados pela PDS Biotechnology , em USD.
- Cap. de mercado
- 136,5 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -31,5 mi | -34,5 mi | |
| 0 | -36,3 mi | -37,6 mi | |
| 0 | -43 mi | -42,9 mi | |
| 0 | -41,7 mi | -40,9 mi |